ROTH Capital Partners Acts as Sole U.S. Placement Agent
for Viralytics Limited in its A$28.3 Million PIPE

For more information please contact:

Investment Banking
John Chambers
Vice-Chairman and
Head of Healthcare
Investment Banking

(646) 358-1901

Michael Margolis, R.Ph
Managing Director
(646) 358-1902


Warren Dunnavant II
(646) 358-1903

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703


Nazan Akdeniz
Senior Vice President
(949) 720-5740


Lou Ellis
Senior Vice President
(949) 720-5739

Transaction Information

Viralytics Limited (Viralytics) has completed a placement of 46,118,270 shares to international and domestic investors at an issue price of A$0.615 per share to raise A$28,362,736. The placement was significantly oversubscribed with strong demand from international specialist healthcare investment funds.


As a result of the placement OrbiMed Advisors becomes a substantial shareholder in Viralytics. Existing shareholders who participated in the placement included Biotechnology Value Fund, L.P. and other affiliates of BVF Partners L.P.


The funds from this capital raise will enable the more rapid advancement of the clinical program, in particular acceleration of the collaborative study with Merck assessing CAVATAK™ in combination with KEYTRUDA® in late stage bladder and lung cancer patients (STORM trial); completion of the CANON trial in patients with non-muscle invasive bladder cancer (and potential extension into a phase 2 study); and the completion of the CAPRA and MITCI studies in melanoma patients assessing CAVATAK in combination with the blockbuster checkpoint inhibitors, KEYTRUDA® and YERVOY® respectively. The funds will also enable initiation of further clinical trials including a study to assess CAVATAK delivered intravenously in combination with a checkpoint inhibitor in melanoma patients and new CAVATAK studies in other cancer types.


ROTH Capital Partners acted as Sole U.S. Placement Agent in the transaction.


About Viralytics Limited
Viralytics is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of certain viruses to preferentially infect and kill cancer cells. Our lead product candidate is CAVATAK™, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21), now being evaluated in Phase 1 and 2 clinical trials. CAVATAK binds to specific receptor proteins highly expressed on a range of cancer cell types, and acts to destroy local as well as metastatic tumour cells through cell lysis and the potential generation of a specific immune response against the cancer cells. Through these selective mechanisms of action, our therapies are designed to provide greater tolerability and efficacy, offering hope of an improved quality of life to patients with cancers that are difficult to treat with current therapeutic approaches. For more information, please visit (Source: Company Website | 12/14/15)


About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit

About ROTH Investment Banking Venture Finance Institutional Sales & Trading
Research Corporate Services Marketing & Conferences Press Room

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2015.